$MDXG
MIMEDX GROUP, INC.

2023 Q4 Form 10-Q Financial Statement

#000137633923000069 Filed on October 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $86.83M $81.71M
YoY Change 16.75% 20.72%
Cost Of Revenue $13.84M $14.79M
YoY Change -3.67% 21.35%
Gross Profit $72.99M $66.92M
YoY Change 21.64% 20.58%
Gross Profit Margin 84.06% 81.9%
Selling, General & Admin $54.35M $52.57M
YoY Change 8.81% -1.69%
% of Gross Profit 74.46% 78.56%
Research & Development $3.175M
YoY Change -46.67%
% of Gross Profit 4.74%
Depreciation & Amortization $803.0K $653.0K
YoY Change -17.89% -21.42%
% of Gross Profit 1.1% 0.98%
Operating Expenses $49.04M $55.75M
YoY Change -11.69% -6.2%
Operating Profit $23.95M $10.82M
YoY Change 435.43% -252.27%
Interest Expense -$1.205M -$1.680M
YoY Change -16.9% 32.28%
% of Operating Profit -5.03% -15.53%
Other Income/Expense, Net -$372.0K -$11.00K
YoY Change 12300.0%
Pretax Income $25.31M $9.125M
YoY Change -6657.77% -208.98%
Income Tax -$37.38M $591.0K
% Of Pretax Income -147.65% 6.48%
Net Earnings $56.23M $8.534M
YoY Change -2764.88% -201.28%
Net Earnings / Revenue 64.76% 10.44%
Basic Earnings Per Share $0.06
Diluted Earnings Per Share $0.23 $0.06
COMMON SHARES
Basic Shares Outstanding 116.4M shares 116.1M shares
Diluted Shares Outstanding 119.3M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.00M $81.20M
YoY Change 24.34% 10.9%
Cash & Equivalents $82.00M $81.16M
Short-Term Investments
Other Short-Term Assets $1.745M $2.311M
YoY Change -33.68% -10.5%
Inventory $21.02M $19.07M
Prepaid Expenses $5.624M $2.954M
Receivables $53.87M $49.01M
Other Receivables $0.00 $0.00
Total Short-Term Assets $164.3M $154.5M
YoY Change 22.4% 13.57%
LONG-TERM ASSETS
Property, Plant & Equipment $9.106M $9.500M
YoY Change -19.1% -18.38%
Goodwill $19.44M $19.44M
YoY Change -2.68% -2.68%
Intangibles $5.257M $5.395M
YoY Change -10.17% 8.07%
Long-Term Investments
YoY Change
Other Assets $205.0K $149.0K
YoY Change 38.51% -0.67%
Total Long-Term Assets $74.79M $34.52M
YoY Change 100.86% -6.09%
TOTAL ASSETS
Total Short-Term Assets $164.3M $154.5M
Total Long-Term Assets $74.79M $34.52M
Total Assets $239.0M $189.0M
YoY Change 39.44% 9.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.048M $9.170M
YoY Change 2.27% 3.97%
Accrued Expenses $9.361M $9.444M
YoY Change -15.09% -14.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.000M
YoY Change
Total Short-Term Liabilities $46.01M $43.63M
YoY Change 5.63% -4.87%
LONG-TERM LIABILITIES
Long-Term Debt $48.10M $48.97M
YoY Change -1.02% 1.01%
Other Long-Term Liabilities $2.223M $2.605M
YoY Change -53.43% -52.56%
Total Long-Term Liabilities $50.32M $51.57M
YoY Change -5.71% -4.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.01M $43.63M
Total Long-Term Liabilities $50.32M $51.57M
Total Liabilities $96.33M $95.20M
YoY Change -0.61% -4.63%
SHAREHOLDERS EQUITY
Retained Earnings -$133.7M -$187.2M
YoY Change -30.34% -2.26%
Common Stock $146.0K $116.0K
YoY Change 28.07% 1.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $142.7M $1.330M
YoY Change
Total Liabilities & Shareholders Equity $239.0M $189.0M
YoY Change 39.44% 9.39%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $56.23M $8.534M
YoY Change -2764.88% -201.28%
Depreciation, Depletion And Amortization $803.0K $653.0K
YoY Change -17.89% -21.42%
Cash From Operating Activities $10.26M $12.79M
YoY Change -282.38% 1233.68%
INVESTING ACTIVITIES
Capital Expenditures $481.0K $640.0K
YoY Change -71.85% -271.12%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$481.0K -$640.0K
YoY Change -71.85% 71.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.940M 370.0K
YoY Change -13645.45% 184.62%
NET CHANGE
Cash From Operating Activities 10.26M 12.79M
Cash From Investing Activities -481.0K -640.0K
Cash From Financing Activities -8.940M 370.0K
Net Change In Cash 836.0K 12.52M
YoY Change -111.5% 1651.05%
FREE CASH FLOW
Cash From Operating Activities $10.26M $12.79M
Capital Expenditures $481.0K $640.0K
Free Cash Flow $9.776M $12.15M
YoY Change -233.32% 811.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
187500000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
116000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
114000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171430000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81712000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67689000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234645000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
193466000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14790000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12188000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
40792000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33947000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
66922000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
55501000 usd
us-gaap Gross Profit
GrossProfit
193853000 usd
us-gaap Gross Profit
GrossProfit
159519000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52571000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53475000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
156773000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
158838000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3175000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5953000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18168000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9125000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8373000 usd
us-gaap Depreciation
Depreciation
2549000 usd
CY2023Q3 us-gaap Cash
Cash
81164000 usd
CY2022Q4 us-gaap Cash
Cash
65950000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
19441000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
19976000 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5395000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5852000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
149000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
148000 usd
CY2023Q3 us-gaap Assets
Assets
189022000 usd
CY2022Q4 us-gaap Assets
Assets
171430000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9170000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8847000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23159000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21852000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9444000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11024000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1854000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1834000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
43627000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43557000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48966000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48594000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2605000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4773000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
95198000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
96924000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
100000 shares
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
100000 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
100000 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
100000 shares
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
100000 shares
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
100000 shares
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
92494000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
92494000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116359748 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116359748 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113705447 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113705447 shares
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
188369000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173804000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187155000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191906000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1330000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-17988000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189022000 usd
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
208000 usd
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
0 usd
us-gaap Restructuring Charges
RestructuringCharges
3464000 usd
us-gaap Restructuring Charges
RestructuringCharges
0 usd
CY2022Q3 mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
3001000 usd
mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
4652000 usd
mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
8771000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
190000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
175000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
570000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
519000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10226000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-26038000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1270000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-4864000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-3566000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5320000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
591000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29783000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6761000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10096000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-433000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34667000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116298146 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113448251 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115528067 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112650713 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
119327709 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113448251 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115528067 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112650713 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-12666000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4388000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
386000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
688000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
8534000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1330000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-13603000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2372000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
137000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8426000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-19520000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-17988000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12793000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1368000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
406000 usd
us-gaap Net Income Loss
NetIncomeLoss
4751000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1330000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10798000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
574000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1191000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29783000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-19520000 usd
us-gaap Net Income Loss
NetIncomeLoss
4751000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29783000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12793000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10798000 usd
mdxg Impairment Of Clinical Trial Assets
ImpairmentOfClinicalTrialAssets
1974000 usd
mdxg Impairment Of Clinical Trial Assets
ImpairmentOfClinicalTrialAssets
0 usd
us-gaap Depreciation
Depreciation
2054000 usd
us-gaap Depreciation
Depreciation
2549000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
959000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
931000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
737000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2817000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
570000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
519000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
535000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
373000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
348000 usd
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
70000 usd
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
69000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
17000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6659000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5885000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3718000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1024000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
323000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1511000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1289000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1041000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1560000 usd
mdxg Payments For Application Costs Patent
PaymentsForApplicationCostsPatent
114000 usd
mdxg Payments For Application Costs Patent
PaymentsForApplicationCostsPatent
128000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
24000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1674000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-951000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
406000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
574000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
36000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
29000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1191000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
370000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-646000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15214000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13866000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65950000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87083000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81164000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73217000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10547000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6855000 usd
CY2023Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, management’s assessment of the Company’s ability to continue as a going concern, estimate of fair value and the probable achievement of share-based payments, estimates of returns and allowances, and valuation of deferred tax assets.</span></div>
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
838000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
810000 usd
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
51579000 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
46867000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2574000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3783000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49005000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43084000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2196000 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3471000 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
447000 usd
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
426000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
69000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
67000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2574000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3830000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3783000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1187000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
737000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2817000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1946000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
174000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3830000 usd
CY2023Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
3213000 usd
CY2022Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
2941000 usd
CY2023Q3 mdxg Accrued Rebates
AccruedRebates
1244000 usd
CY2022Q4 mdxg Accrued Rebates
AccruedRebates
707000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1025000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7683000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5518000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
19068000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
13183000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
189000 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
189000 usd
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
45029000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
43783000 usd
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
37935000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
35927000 usd
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7094000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7856000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
653000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
831000 usd
us-gaap Depreciation
Depreciation
2054000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
19976000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
535000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
19441000 usd
CY2023Q3 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 usd
CY2022Q3 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 usd
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4447000 usd
CY2023Q3 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
910000 usd
CY2022Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
659000 usd
CY2023Q3 mdxg Accrued Administrative Fees Current
AccruedAdministrativeFeesCurrent
713000 usd
CY2022Q4 mdxg Accrued Administrative Fees Current
AccruedAdministrativeFeesCurrent
638000 usd
CY2023Q3 mdxg Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
694000 usd
CY2022Q4 mdxg Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
90000 usd
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
547000 usd
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
10969000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7680000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3289000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
10923000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7110000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3813000 usd
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
13075000 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5395000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
12962000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5852000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
190000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
759000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
364000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
210000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
209000 usd
CY2023Q3 mdxg Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
1557000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3289000 usd
CY2023Q3 mdxg Accrued Travel
AccruedTravel
259000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
839000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9444000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
50000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 usd
CY2023Q3 mdxg Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
0 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
8534000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8426000 usd
us-gaap Net Income Loss
NetIncomeLoss
4751000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29783000 usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1773000 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1670000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5184000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4884000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6761000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10096000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-433000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34667000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116298146 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113448251 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115528067 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112650713 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6761000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10096000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-433000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34667000 usd
CY2023Q3 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
1773000 usd
CY2022Q3 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
1670000 usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
5184000 usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
4884000 usd
CY2023Q3 mdxg Convertible Preferred Stock Dividends Antidilutive Adjustments Net Of Tax
ConvertiblePreferredStockDividendsAntidilutiveAdjustmentsNetOfTax
1773000 usd
CY2022Q3 mdxg Convertible Preferred Stock Dividends Antidilutive Adjustments Net Of Tax
ConvertiblePreferredStockDividendsAntidilutiveAdjustmentsNetOfTax
1670000 usd
mdxg Convertible Preferred Stock Dividends Antidilutive Adjustments Net Of Tax
ConvertiblePreferredStockDividendsAntidilutiveAdjustmentsNetOfTax
5184000 usd
mdxg Convertible Preferred Stock Dividends Antidilutive Adjustments Net Of Tax
ConvertiblePreferredStockDividendsAntidilutiveAdjustmentsNetOfTax
4884000 usd
CY2023Q3 mdxg Dilutive Adjustments To Income Loss Available To Common Stockholders
DilutiveAdjustmentsToIncomeLossAvailableToCommonStockholders
0 usd
CY2022Q3 mdxg Dilutive Adjustments To Income Loss Available To Common Stockholders
DilutiveAdjustmentsToIncomeLossAvailableToCommonStockholders
0 usd
mdxg Dilutive Adjustments To Income Loss Available To Common Stockholders
DilutiveAdjustmentsToIncomeLossAvailableToCommonStockholders
0 usd
mdxg Dilutive Adjustments To Income Loss Available To Common Stockholders
DilutiveAdjustmentsToIncomeLossAvailableToCommonStockholders
0 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
6761000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10096000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-433000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34667000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116298146 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113448251 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115528067 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112650713 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3029563 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
119327709 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113448251 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115528067 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112650713 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30445997 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29269481 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30925149 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28858049 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
933894 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3694000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.77
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
62599 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
423213 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.81
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4142082 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M21D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13178214 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
448082 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P0Y7M6D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
174314 usd
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.065
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.107
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006
us-gaap Interest Paid Net
InterestPaidNet
4496000 usd
us-gaap Interest Paid Net
InterestPaidNet
3233000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
210000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
184000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1368000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
126000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
353000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
37000 usd
CY2019Q1 mdxg Contingency Loss Number Of Securities Class Actions
ContingencyLossNumberOfSecuritiesClassActions
2 class_action
CY2023Q3 mdxg Revenue From Contract With Customer Number Service Sites
RevenueFromContractWithCustomerNumberServiceSites
3 service_site
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67689000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234645000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
193466000 usd
CY2023Q3 mdxg Number Of Products
NumberOfProducts
2 product
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81712000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67689000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234645000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
193466000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81712000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14790000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52571000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3175000 usd
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
208000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
190000 usd
CY2023Q3 mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
-38000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10816000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
653000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4388000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67689000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12188000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53475000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5953000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
175000 usd
CY2022Q3 mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
3001000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7103000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
831000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2372000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234645000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
40792000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
156773000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18168000 usd
us-gaap Restructuring Charges
RestructuringCharges
3464000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
570000 usd
mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
4652000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10226000 usd
us-gaap Depreciation
Depreciation
2054000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12793000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
193466000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33947000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
158838000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17429000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
519000 usd
mdxg Investigation Restatement And Related
InvestigationRestatementAndRelated
8771000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-26038000 usd
us-gaap Depreciation
Depreciation
2549000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10798000 usd

Files In Submission

Name View Source Status
mdxg-20230930_cal.xml Edgar Link unprocessable
mdxg-20230930_def.xml Edgar Link unprocessable
mdxg-20230930_lab.xml Edgar Link unprocessable
0001376339-23-000069-index-headers.html Edgar Link pending
0001376339-23-000069-index.html Edgar Link pending
0001376339-23-000069.txt Edgar Link pending
0001376339-23-000069-xbrl.zip Edgar Link pending
a20230930-10qex311final.htm Edgar Link pending
a20230930-10qex312final.htm Edgar Link pending
a20230930-10qex321final.htm Edgar Link pending
a20230930-10qex322final.htm Edgar Link pending
ex106-steinseparationagree.htm Edgar Link pending
ex107-carlsonseparationagr.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0a.jpg Edgar Link pending
image_1a.jpg Edgar Link pending
mdxg-20230930.htm Edgar Link pending
mdxg-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mdxg-20230930_pre.xml Edgar Link unprocessable
mdxg-20230930_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending